Saccharomyces cerevisiae asosida SARS-CoV-2 S1 rekombinant oqsilini olish texnologiyasini o‘rganish

Study of the technology for producing the recombinant SARS-CoV-2 S1 protein based on Saccharomyces cerevisiae

Article Sidebar

PDF (Uzbek)
Published: 2026-10-30
DOI: https://doi.org/10.66073/ReFocus-Conf/3010041
Keywords:
SARS-CoV-2, Saccharomyces cerevisiae, S1 protein, recombinant protein, pYES2-S1-Zeo, subunit vaccine, SDS-PAGE, Western blot

Main Article Content

Toshboyeva Fotima Nuriddin kizi
National University of Uzbekistan named after Mirzo Ulugbek
Ayubov M.S.
Center of Genomics and Bioinformatics of the Academy of Sciences of the Republic of Uzbekistan
Ravshanov Hamrokul Toymurod ugli
National University of Uzbekistan named after Mirzo Ulugbek

Abstract

This article examines the use of Saccharomyces cerevisiae as an expression system for producing a recombinant SARS-CoV-2 antigen within a subunit vaccine development platform. The study focuses on the pYES2-S1-Zeo construct intended for expression of the SARS-CoV-2 S1 protein in yeast cells. According to the dissertation materials, S. cerevisiae was isolated from baker’s yeast, culture purity was checked microscopically, and a recombinant expression approach was applied. SDS-PAGE and Western blotting were selected for evaluation of recombinant protein expression, with a predicted molecular mass of 61 kDa for S1. The available materials support the study of S. cerevisiae as a recombinant antigen expression platform.

Article Details

Issue

Vol. 1 No. 8 (2026): Status and Development Prospects of Fundamental and Applied Microbiology: The Viewpoint of Young Scientists

Section

Biotechnology, Molecular Biology and Bioinformatics
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

Toshboyeva Fotima Nuriddin kizi, Ayubov M.S., & Ravshanov Hamrokul Toymurod ugli. (2026). Study of the technology for producing the recombinant SARS-CoV-2 S1 protein based on Saccharomyces cerevisiae. Partner Conferences of the International Scientific Journal Research Focus, 1(8), 164-166. https://doi.org/10.66073/ReFocus-Conf/3010041

References

Dong Y, Dai T, Wang B, Zhang L, Zeng LH, Huang J, et al. The way of SARS-CoV-2 vaccine development: success and challenges. Signal Transduct Target Ther. 2021;6(1):387. doi:10.1038/s41392-021-00796-w. DOI: https://doi.org/10.1038/s41392-021-00796-w

Khalid K, Lim HX, Hwang JS, Poh CL. The development of epitope-based recombinant protein vaccines against SARS-CoV-2. AAPS J. 2024;26(5):93. doi:10.1208/s12248-024-00963-1. DOI: https://doi.org/10.1208/s12248-024-00963-1

Pardi N, Krammer F. mRNA vaccines for infectious diseases—advances, challenges and opportunities. Nat Rev Drug Discov. 2024;23(11):838-861. doi:10.1038/s41573-024-01042-y. DOI: https://doi.org/10.1038/s41573-024-01042-y